1. Home
  2. DOUG vs MDWD Comparison

DOUG vs MDWD Comparison

Compare DOUG & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Douglas Elliman Inc.

DOUG

Douglas Elliman Inc.

HOLD

Current Price

$2.82

Market Cap

219.1M

Sector

Real Estate

ML Signal

HOLD

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$18.97

Market Cap

230.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DOUG
MDWD
Founded
1911
2000
Country
United States
Israel
Employees
N/A
N/A
Industry
Building operators
Medicinal Chemicals and Botanical Products
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
219.1M
230.7M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
DOUG
MDWD
Price
$2.82
$18.97
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$37.50
AVG Volume (30 Days)
292.1K
95.0K
Earning Date
11-04-2025
11-20-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,030,928,000.00
$20,932,000.00
Revenue This Year
$17.61
$15.89
Revenue Next Year
N/A
$25.33
P/E Ratio
N/A
N/A
Revenue Growth
6.67
6.15
52 Week Low
$1.48
$14.14
52 Week High
$3.20
$22.51

Technical Indicators

Market Signals
Indicator
DOUG
MDWD
Relative Strength Index (RSI) 62.49 59.99
Support Level $2.66 $18.71
Resistance Level $2.70 $19.63
Average True Range (ATR) 0.12 0.71
MACD 0.04 0.18
Stochastic Oscillator 87.27 79.22

Price Performance

Historical Comparison
DOUG
MDWD

About DOUG Douglas Elliman Inc.

Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees. It derives revenue from Real Estate Brokerage segment.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: